Statement re. Suspension
Trading in SkinBioTherapeutics plc ordinary shares has been suspended effective immediately due to the company's failure to announce its interim results for the six months ended 31 December 2025 by the required deadline of 31 March 2026. The company anticipates trading will resume upon the publication of these interim results, which are expected to be released following the conclusion of an ongoing Board investigation and an independent forensic review by FRP Advisory, both of which are progressing and are hoped to be finalized later this month.
Select text to share a quote on X · sign in to keep highlights & notes in your SBTX notes
1 April 2026 - the Board of SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that trading in the Company's ordinary shares will be suspended with effect from 7.30am today as a consequence of the Company not announcing the interim results for the 6 months ended 31 December 2025 ("Interim Results") by 31 March 2026, as required by the AIM Rules for Companies.
The previously announced Board investigation and the independent, forensic review being undertaken by FRP Advisory continues to progress and the Board is hopeful that these will be concluded later this month. Trading in the Company's ordinary shares is anticipated to resume upon the publication of the Interim Results.
The Board will update shareholders on the result of the forensic review and Board investigation as soon as possible.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.